New Analytic Tools for aHUS and C3G Diagnosis (COMPRare)
Hemolytic-Uremic Syndrome, Membranoproliferative Glomerulonephritis, Healthy
About this trial
This is an interventional diagnostic trial for Hemolytic-Uremic Syndrome focused on measuring Complement-mediated kidney diseases, Blood and tissue biomarkers, Assay standardization, Glycocalyx, Characterization of variants of unknown significance
Eligibility Criteria
Aim 1 Inclusion Criteria: Male and female patients (children and adults) with C3G diagnosis Biobank written informed consent Aim 2 Inclusion criteria Male and female patients (children and adults) with aHUS diagnosis in acute phase (before any treatment), or in remission either untreated or undergoing anti-C5 treatment at standard dosing Written informed consent Exclusion criteria Stx-associated HUS TTP (ADAMTS13<10%) Plasma therapy within 2 weeks from blood sampling
Sites / Locations
- Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò"
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Patients
Healthy controls